In	O	0,2
our	O	3,6
experience,	O	7,18
some	O	19,23
patients	O	24,32
do	O	33,35
require	O	36,43
longer	O	44,50
courses	O	51,58
of	O	59,61
antibiotic	B-KP	62,72
therapy	I-KP	73,80
for	O	81,84
effective	O	85,94
treatment	O	95,104
of	O	105,107
Lyme	B-KP	108,112
arthritis.	I-KP	113,123

[12]	O	124,128
Thus,	O	129,134
if	O	135,137
there	O	138,143
is	O	144,146
mild	O	147,151
residual	O	152,160
joint	O	161,166
swelling	O	167,175
after	O	176,181
a	O	182,183
30-day	O	184,190
course	O	191,197
of	O	198,200
oral	B-KP	201,205
antibiotics,	I-KP	206,218
we	O	219,221
repeat	O	222,228
the	O	229,232
oral	B-KP	233,237
antibiotic	I-KP	238,248
regimen	O	249,256
for	O	257,260
another	O	261,268
30	O	269,271
days.	O	272,277

However,	O	278,286
for	O	287,290
patients	O	291,299
who	O	300,303
continue	O	304,312
to	O	313,315
have	O	316,320
moderate-to-severe	O	321,339
joint	O	340,345
swelling	O	346,354
after	O	355,360
a	O	361,362
30-day	O	363,369
course	O	370,376
of	O	377,379
oral	B-KP	380,384
antibiotics,	I-KP	385,397
we	O	398,400
treat	O	401,406
with	O	407,411
IV	B-KP	412,414
ceftriaxone,	I-KP	415,427
2gm/day.	O	428,436

Although	O	437,445
there	O	446,451
is	O	452,454
trend	O	455,460
toward	O	461,467
greater	O	468,475
efficacy	O	476,484
with	O	485,489
4	O	490,491
weeks	O	492,497
compared	O	498,506
with	O	507,511
2	O	512,513
weeks	O	514,519
of	O	520,522
antibiotics,	B-KP	523,535
there	O	536,541
is	O	542,544
also	O	545,549
a	O	550,551
greater	O	552,559
frequency	O	560,569
of	O	570,572
adverse	O	573,580
events.38	O	581,590
Thus,	O	591,596
our	O	597,600
practice	O	601,609
is	O	610,612
to	O	613,615
prescribe	O	616,625
a	O	626,627
4-week	O	628,634
course	O	635,641
of	O	642,644
IV	B-KP	645,647
therapy,	I-KP	648,656
but	O	657,660
to	O	661,663
monitor	O	664,671
the	O	672,675
patient	O	676,683
closely	O	684,691
and	O	692,695
to	O	696,698
stop	O	699,703
the	O	704,707
antibiotic	B-KP	708,718
if	O	719,721
complications	O	722,735
occur.\nEven	O	736,748
in	O	749,751
patients	O	752,760
who	O	761,764
had	O	765,768
minimal	O	769,776
or	O	777,779
no	O	780,782
improvement	O	783,794
with	O	795,799
oral	B-KP	800,804
doxycycline,	I-KP	805,817
we	O	818,820
typically	O	821,830
observe	O	831,838
moderate	O	839,847
improvement	O	848,859
or	O	860,862
even	O	863,867
complete	O	868,876
resolution	O	877,887
of	O	888,890
arthritis	O	891,900
with	O	901,905
IV	B-KP	906,908
therapy.	I-KP	909,917

Moreover,	O	918,927
even	O	928,932
in	O	933,935
those	O	936,941
with	O	942,946
persistent	B-KP	947,957
joint	I-KP	958,963
inflammation,	I-KP	964,977
the	O	978,981
synovitis	B-KP	982,991
tends	O	992,997
to	O	998,1000
change	O	1001,1007
after	O	1008,1013
IV	B-KP	1014,1016
therapy	I-KP	1017,1024
with	O	1025,1029
decreased	O	1030,1039
size	O	1040,1044
of	O	1045,1047
effusions	O	1048,1057
but	O	1058,1061
continued	O	1062,1071
synovial	B-KP	1072,1080
tissue	I-KP	1081,1087
hypertrophy	I-KP	1088,1099
and	O	1100,1103
inflammation.	O	1104,1117

Courses	O	1118,1125
of	O	1126,1128
longer	O	1129,1135
than	O	1136,1140
30	O	1141,1143
days	O	1144,1148
of	O	1149,1151
IV	B-KP	1152,1154
antibiotics	I-KP	1155,1166
seem	O	1167,1171
not	O	1172,1175
to	O	1176,1178
be	O	1179,1181
beneficial	O	1182,1192
and	O	1193,1196
may	O	1197,1200
be	O	1201,1203
associated	O	1204,1214
with	O	1215,1219
a	O	1220,1221
still	O	1222,1227
greater	O	1228,1235
frequency	O	1236,1245
of	O	1246,1248
adverse	O	1249,1256
effect.	O	1257,1264

[39]	O	1265,1269
Additionally,	O	1270,1283
a	O	1284,1285
recent	O	1286,1292
double-blind,	O	1293,1306
randomized,	O	1307,1318
placebo-controlled	O	1319,1337
study	O	1338,1343
of	O	1344,1346
patients	O	1347,1355
in	O	1356,1358
Europe	O	1359,1365
did	O	1366,1369
not	O	1370,1373
find	O	1374,1378
a	O	1379,1380
benefit	O	1381,1388
of	O	1389,1391
additional	O	1392,1402
oral	B-KP	1403,1407
amoxicillin	I-KP	1408,1419
therapy	I-KP	1420,1427
following	O	1428,1437
treatment	O	1438,1447
with	O	1448,1452
IV	B-KP	1453,1455
ceftriaxone.	I-KP	1456,1468

[40]	O	1469,1473
A	O	1474,1475
number	O	1476,1482
of	O	1483,1485
newer	O	1486,1491
oral	O	1492,1496
antibiotics	B-KP	1497,1508
in	O	1509,1511
an	O	1512,1514
FDA	O	1515,1518
approved	O	1519,1527
drug	O	1528,1532
library,	O	1533,1541
including	O	1542,1551
daptomycin,	B-KP	1552,1563
carbomycin,	B-KP	1564,1575
and	O	1576,1579
cefoperazone,	B-KP	1580,1593
have	O	1594,1598
been	O	1599,1603
shown	O	1604,1609
to	O	1610,1612
have	O	1613,1617
marked	O	1618,1624
efficacy	O	1625,1633
against	O	1634,1641
persisting	O	1642,1652
spirochetes	B-KP	1653,1664
in	O	1665,1667
culture,	O	1668,1676
[41]	O	1677,1681
but	O	1682,1685
it	O	1686,1688
is	O	1689,1691
not	O	1692,1695
yet	O	1696,1699
known	O	1700,1705
whether	O	1706,1713
such	O	1714,1718
antibiotics	B-KP	1719,1730
would	O	1731,1736
be	O	1737,1739
effective	O	1740,1749
in	O	1750,1752
patients	O	1753,1761
with	O	1762,1766
Lyme	B-KP	1767,1771
arthritis	I-KP	1772,1781
that	O	1782,1786
is	O	1787,1789
more	O	1790,1794
difficult	O	1795,1804
to	O	1805,1807
treat.	O	1808,1814

In	O	0,2
our	O	3,6
experience,	O	7,18
some	O	19,23
patients	O	24,32
do	O	33,35
require	O	36,43
longer	O	44,50
courses	O	51,58
of	O	59,61
antibiotic	B-KP	62,72
therapy	I-KP	73,80
for	O	81,84
effective	O	85,94
treatment	O	95,104
of	O	105,107
Lyme	B-KP	108,112
arthritis.	I-KP	113,123

[12]	O	124,128
Thus,	O	129,134
if	O	135,137
there	O	138,143
is	O	144,146
mild	O	147,151
residual	O	152,160
joint	O	161,166
swelling	O	167,175
after	O	176,181
a	O	182,183
30-day	O	184,190
course	O	191,197
of	O	198,200
oral	B-KP	201,205
antibiotics,	I-KP	206,218
we	O	219,221
repeat	O	222,228
the	O	229,232
oral	B-KP	233,237
antibiotic	I-KP	238,248
regimen	O	249,256
for	O	257,260
another	O	261,268
30	O	269,271
days.	O	272,277

However,	O	278,286
for	O	287,290
patients	O	291,299
who	O	300,303
continue	O	304,312
to	O	313,315
have	O	316,320
moderate-to-severe	O	321,339
joint	O	340,345
swelling	O	346,354
after	O	355,360
a	O	361,362
30-day	O	363,369
course	O	370,376
of	O	377,379
oral	B-KP	380,384
antibiotics,	I-KP	385,397
we	O	398,400
treat	O	401,406
with	O	407,411
IV	B-KP	412,414
ceftriaxone,	I-KP	415,427
2gm/day.	O	428,436

Although	O	437,445
there	O	446,451
is	O	452,454
trend	O	455,460
toward	O	461,467
greater	O	468,475
efficacy	O	476,484
with	O	485,489
4	O	490,491
weeks	O	492,497
compared	O	498,506
with	O	507,511
2	O	512,513
weeks	O	514,519
of	O	520,522
antibiotics,	B-KP	523,535
there	O	536,541
is	O	542,544
also	O	545,549
a	O	550,551
greater	O	552,559
frequency	O	560,569
of	O	570,572
adverse	O	573,580
events.38	O	581,590
Thus,	O	591,596
our	O	597,600
practice	O	601,609
is	O	610,612
to	O	613,615
prescribe	O	616,625
a	O	626,627
4-week	O	628,634
course	O	635,641
of	O	642,644
IV	B-KP	645,647
therapy,	I-KP	648,656
but	O	657,660
to	O	661,663
monitor	O	664,671
the	O	672,675
patient	O	676,683
closely	O	684,691
and	O	692,695
to	O	696,698
stop	O	699,703
the	O	704,707
antibiotic	B-KP	708,718
if	O	719,721
complications	O	722,735
occur.\nEven	O	736,748
in	O	749,751
patients	O	752,760
who	O	761,764
had	O	765,768
minimal	O	769,776
or	O	777,779
no	O	780,782
improvement	O	783,794
with	O	795,799
oral	B-KP	800,804
doxycycline,	I-KP	805,817
we	O	818,820
typically	O	821,830
observe	O	831,838
moderate	O	839,847
improvement	O	848,859
or	O	860,862
even	O	863,867
complete	O	868,876
resolution	O	877,887
of	O	888,890
arthritis	O	891,900
with	O	901,905
IV	B-KP	906,908
therapy.	I-KP	909,917

Moreover,	O	918,927
even	O	928,932
in	O	933,935
those	O	936,941
with	O	942,946
persistent	B-KP	947,957
joint	I-KP	958,963
inflammation,	I-KP	964,977
the	O	978,981
synovitis	B-KP	982,991
tends	O	992,997
to	O	998,1000
change	O	1001,1007
after	O	1008,1013
IV	B-KP	1014,1016
therapy	I-KP	1017,1024
with	O	1025,1029
decreased	O	1030,1039
size	O	1040,1044
of	O	1045,1047
effusions	O	1048,1057
but	O	1058,1061
continued	O	1062,1071
synovial	B-KP	1072,1080
tissue	I-KP	1081,1087
hypertrophy	I-KP	1088,1099
and	O	1100,1103
inflammation.	O	1104,1117

Courses	O	1118,1125
of	O	1126,1128
longer	O	1129,1135
than	O	1136,1140
30	O	1141,1143
days	O	1144,1148
of	O	1149,1151
IV	B-KP	1152,1154
antibiotics	I-KP	1155,1166
seem	O	1167,1171
not	O	1172,1175
to	O	1176,1178
be	O	1179,1181
beneficial	O	1182,1192
and	O	1193,1196
may	O	1197,1200
be	O	1201,1203
associated	O	1204,1214
with	O	1215,1219
a	O	1220,1221
still	O	1222,1227
greater	O	1228,1235
frequency	O	1236,1245
of	O	1246,1248
adverse	O	1249,1256
effect.	O	1257,1264

[39]	O	1265,1269
Additionally,	O	1270,1283
a	O	1284,1285
recent	O	1286,1292
double-blind,	O	1293,1306
randomized,	O	1307,1318
placebo-controlled	O	1319,1337
study	O	1338,1343
of	O	1344,1346
patients	O	1347,1355
in	O	1356,1358
Europe	O	1359,1365
did	O	1366,1369
not	O	1370,1373
find	O	1374,1378
a	O	1379,1380
benefit	O	1381,1388
of	O	1389,1391
additional	O	1392,1402
oral	B-KP	1403,1407
amoxicillin	I-KP	1408,1419
therapy	I-KP	1420,1427
following	O	1428,1437
treatment	O	1438,1447
with	O	1448,1452
IV	B-KP	1453,1455
ceftriaxone.	I-KP	1456,1468

[40]	O	1469,1473
A	O	1474,1475
number	O	1476,1482
of	O	1483,1485
newer	O	1486,1491
oral	O	1492,1496
antibiotics	B-KP	1497,1508
in	O	1509,1511
an	O	1512,1514
FDA	O	1515,1518
approved	O	1519,1527
drug	O	1528,1532
library,	O	1533,1541
including	O	1542,1551
daptomycin,	B-KP	1552,1563
carbomycin,	B-KP	1564,1575
and	O	1576,1579
cefoperazone,	B-KP	1580,1593
have	O	1594,1598
been	O	1599,1603
shown	O	1604,1609
to	O	1610,1612
have	O	1613,1617
marked	O	1618,1624
efficacy	O	1625,1633
against	O	1634,1641
persisting	O	1642,1652
spirochetes	B-KP	1653,1664
in	O	1665,1667
culture,	O	1668,1676
[41]	O	1677,1681
but	O	1682,1685
it	O	1686,1688
is	O	1689,1691
not	O	1692,1695
yet	O	1696,1699
known	O	1700,1705
whether	O	1706,1713
such	O	1714,1718
antibiotics	B-KP	1719,1730
would	O	1731,1736
be	O	1737,1739
effective	O	1740,1749
in	O	1750,1752
patients	O	1753,1761
with	O	1762,1766
Lyme	B-KP	1767,1771
arthritis	I-KP	1772,1781
that	O	1782,1786
is	O	1787,1789
more	O	1790,1794
difficult	O	1795,1804
to	O	1805,1807
treat.	O	1808,1814

